Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Board

Company Overview

Team

Values

Clinical Advisers

Corporate Directory

Corporate Governance

About Us

Presentations

In the News

Video Updates

Communication

Shareholder Services

US Shareholders

Investor Fact Sheet

Share Price

Announcements

Reports

Research Reports

Investor FAQs

Updates

Top 20 Shareholders

Investor Centre

Clinical Trial

Home

Webinars

Contact

Montserrat

Amplia Therapeutics Limited

upload.jpg

Amplia has announced that an additional confirmed partial response (PR) has been recorded in the ongoing ACCENT trial, bringing the total number of confirmed PRs to 16 out of 55 patients enrolled.

A confirmed partial response is a formal designation of response where tumour shrinkage greater than 30% is recorded and sustained for two or more months and where no new cancerous lesions have been detected.

This brings the objective response rate of 29% in the trial evaluating narmafotinib in combination with the chemotherapies gemcitabine and Abraxane in patients with advanced pancreatic cancer.

Amplia CEO and MD Dr Chris Burns commented:

"An additional confirmed PR adds to the promising data already recorded in the ACCENT trial. With 20 patients still on study we are hopeful that further PR's will be recorded in the future."

Additional Partial Response Observed in ACCENT Pancreatic Cancer Trial